Abstract: A polypeptide having superoxide dismutase (SOD) activity and/or extracellular vesicles containing SOD is effective for the prevention and/or treatment of respiratory viral infection or diseases caused by respiratory viral infection in a subject. The polypeptide has SOD activity derived from a Bacillus amyloliquefaciens strain and/or extracellular vesicles containing SOD derived from a Bacillus subtillis strain is useful for the prevention and/or treatment of respiratory viral infection or diseases caused by respiratory viral infection in a subject.
Type:
Application
Filed:
November 23, 2021
Publication date:
January 4, 2024
Applicant:
GENOFOCUS CO., LTD.
Inventors:
Jae Gu PAN, Eui Joong KIM, Jeong Hyun KIM
Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
Type:
Application
Filed:
August 9, 2023
Publication date:
January 4, 2024
Inventors:
Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Bum Joon KIM
Abstract: The present invention relates to a method for promoting the formation of mature BDNF and increasing the level of BDNF. The method comprises administering a therapeutically effective amount of a plasminogen pathway activator to a subject. The present invention also relates to a pharmaceutical composition, a product and a kit which comprises the plasminogen pathway activator and are used for promoting the formation of mature BDNF and increasing the BDNF level.
Abstract: The present invention relates to a method for promoting the formation of mature NGF and increasing the expression of NGF. The method comprises administering a therapeutically effective amount of a plasminogen pathway activator to a subject. The present invention further relates to a pharmaceutical composition, a product and a kit comprising the plasminogen pathway activator for promoting the formation of mature NGF and increasing the expression of NGF.
Abstract: Nanoparticles or microgels comprising a polyelectrolyte nanocomplex comprising one or more neuromodulators, a carrier molecule, and a counter ion polymer, wherein the counter ion polymer has a charge enabling it to bind electrostatically to the one or more neuromodulators, methods of their preparation, and methods of treating a disease or condition are disclosed.
Abstract: The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.
Abstract: The invention is based on the finding that endoplasmic reticulum (ER) stress signalling is associated with the pathogenesis of liver disorders such fatty liver, cirrhosis and hepatocellular carcinoma (HCC), and others. The invention identifies novel targets for liver disease therapy which are involved in ER stress signalling, and thereby pertains to compounds and compositions for medical uses, screening approaches to identify therapeutics as well as diagnostic approaches for the identification of disorders or the stratification of certain liver disease patient groups. The invention also pertains to the use of immune checkpoint inhibitors in combination with the compounds or compositions and/or in the treatment of endoplasmic reticulum (ER) stress signalling induced liver cancers.
Type:
Application
Filed:
November 12, 2021
Publication date:
January 4, 2024
Applicant:
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Abstract: The invention relates to methods of treating antibody-mediated rejection in a subject comprising administering C1-INH to the subject according to a schedule with the following steps: (a) intravenously administering one or more iv-doses of C1-INH, (b) subcutaneously administering at least 10 sc-doses of C1-INH over several weeks, wherein each week at least one sc-dose is administered. The invention further relates to a method of treating antibody-mediated rejection in a transplant recipient comprising subcutaneously administering C1-INH over at least 10 weeks, wherein each week at least one sc-dose is administered.
Type:
Application
Filed:
November 18, 2021
Publication date:
January 4, 2024
Applicant:
CSL Behring GmbH
Inventors:
John Roberts, Marc Uknis, Christine Voigt
Abstract: The present application relates to a C-terminus modified human papillomavirus type 6 L1 protein and use thereof. Specifically, the present application relates to a C-terminus modified human papillomavirus (HPV) type 6 L1 protein, an encoded nucleotide thereof, a vector comprising the nucleotide, a cell comprising the vector, a pentamer or virus-like particle composed of the HPV6 L1 protein, a vaccine containing the pentamer or virus-like particle and a vaccine adjuvant, and the use thereof in prevention of HPV infection and HPV infection-related diseases.
Abstract: A reusable battery indicator includes a voltage sensor, a communication circuit communicatively connected to the voltage sensor, an antenna operatively coupled to the communication circuit, and a connector. The connector is electrically connected to the voltage sensor, and the connector is adapted to be removably connected to a battery, thereby providing an electrical connection between the voltage sensor and the battery. An electrical circuit is completed between the voltage sensor and the battery and the voltage sensor. The connection mechanism includes part of an electrical lock and key assembly.
Type:
Application
Filed:
July 10, 2023
Publication date:
January 4, 2024
Inventors:
Joern Riemer, Robert Pavlinsky, Jordan Bourilkov, Steven J. Specht, George Turco, Sergio Coronado
Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular gastric cancer, lung cancer, melanoma and bladder cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.
Type:
Application
Filed:
May 2, 2023
Publication date:
January 4, 2024
Inventors:
Julianna Lisziewicz, Levente Molnár, Eniko Toke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 15, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
Type:
Application
Filed:
November 1, 2021
Publication date:
January 4, 2024
Inventors:
Annaliesa Sybil Anderson, Seema Shridhar Gangolli, Kathrin Ute Jansen, Avvari Krishna Prasad, Michael William Pride, Ingrid Lea Scully, Wendy Jo Watson
Abstract: The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.
Type:
Application
Filed:
May 16, 2023
Publication date:
January 4, 2024
Inventors:
Paul Joseph Dominowski, Dennis L. Foss, Guillermo Gallo, John Morgan Hardham, Richard Lee Krebs, Sandra Ann Marie Lightle, Suman Mahan, Sangita Mediratta, Kaori Mohr, Duncan Mwangi, Sharath K. Rai, Sarah A. Salmon, Shaunak Vora, Lauren Wilmes
Abstract: The present application relates to a C-terminus modified human papillomavirus type 11 L1 protein and the use thereof. Specifically, the present application relates to a C-terminus modified human papillomavirus (HPV) type 11 L1 protein, a nucleotide encoded thereby, a vector containing the nucleotide, a cell containing the vector, a pentamer or virus-like particle composed of the HPV11 L1 protein, and a vaccine containing the pentamer or virus-like particle and a vaccine adjuvant, and the use thereof in the prevention of HPV infection and HPV infection-related diseases.
Abstract: The present disclosure provides a universal influenza virus vaccine. A composition for a universal influenza virus vaccine comprises at least two, preferably more than two, different influenza hemagglutinin (HA) derived antigens. The HA proteins from which the antigens are derived have a hypervariable region located between conserved cysteines at positions 52 and 277, and the hypervariable region is deleted in the antigens. The at least two antigens each have a similarity with HA molecules of more than one influenza serotype in excess of 60, or 70, or 80, as calculated by the emboss explorer cons program.
Type:
Application
Filed:
November 18, 2021
Publication date:
January 4, 2024
Inventors:
Uwe D. STAERZ, Philip C. SPEAR, Yan QI, Janae Wheeler CULL
Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
Abstract: The present invention provides mRNA sequences comprising at least one coding region, encoding for at least one epitope of a protein, or of a fragment, variant or derivative thereof, of a virus of the genus rotavirus. Particularly preferred is the protein respectively the protein cleavage product VP8* of rotavirus. The mRNA sequence may be used as a vaccine or generally as a pharmaceutical composition for prophylaxis or treatment of rotavirus infections.
Abstract: Provided are a newly designed HIV-1 Env trimer protein, and an HIV-1 pseudovirus and virus expressing the Env trimer protein, and the use thereof for the prevention and/or treatment of HIV infection.
Abstract: The present invention provides recombinant vectors encoding a chimeric coronavirus spike protein. The present invention further provides new immunogenic compositions and vaccines comprising these recombinant vectors. Methods of administering these immunogenic compositions and vaccines to animal subjects, including humans, felines, and avians, to protect them against coronaviruses also are included. Methods of making the immunogenic compositions and vaccines alone or in combinations with other protective agents are provided too.
Type:
Application
Filed:
November 11, 2021
Publication date:
January 4, 2024
Applicant:
Intervet Inc.
Inventors:
Martijn Alexander Langereis, Ad De Groof, Paul Vermeij, Berend Jan Bosch
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.
Type:
Application
Filed:
June 26, 2023
Publication date:
January 4, 2024
Inventors:
Alexander Muik, Asaf Poran, Kena Anne Swanson, Qi Yang, Hui Cai, Ugur Sahin, Kayvon Modjarrad
Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
Abstract: Provided herein is a method for preventing a person from an infection by a Coronaviridae virus with a poliomyelitis vaccine. Also provided herein is a method of inducing a protective immune response against a Coronaviridae virus with a poliomyelitis vaccine.
Abstract: The present invention provides a novel antigen for an egg allergy, a method for diagnosing an egg allergy and a kit for diagnosing an egg allergy, a pharmaceutical composition comprising the antigen, an egg, a processed product of an egg, or a bird which lays or has hatched from the egg in which the antigen is eliminated or reduced, a method for producing a processed product of an egg in which the antigen is eliminated or reduced, and a tester for determining the presence or absence of an egg antigen in an object of interest.
Abstract: A method of treating allergic rhinitis and/or rhinoconjunctivitis in a subject, the method comprising administering to a subject in need thereof a therapeutically effective allergen-specific immunotherapy comprising or consisting of: (a) a build-up phase consisting of three weekly subcutaneous injections of a composition comprising one or more antigens; and (b) a maintenance phase consisting of three monthly subcutaneous injections of a composition comprising one or more antigens.
Type:
Application
Filed:
June 30, 2023
Publication date:
January 4, 2024
Inventors:
Pieter-Jan De Kam, Matthew D. Heath, Matthias F. Kramer, Simon J. Hewings, Murray A. Skinner, Kemi Oluwayi
Abstract: The present disclosure provides a process for purifying high-molecular weight bacterial polysaccharides (e.g., cell wall polysaccharides), and polypeptide-polysaccharide conjugates thereof, suitable for use in immunogenic compositions.
Type:
Application
Filed:
August 9, 2023
Publication date:
January 4, 2024
Inventors:
Christopher R. BEHRENS, Paresh AGARWAL, Lu YIN, Peter T. DAVEY, Angie A. SEDRA
Abstract: The present invention discloses a method of treating, preventing or ameliorating tumor growth by administering a therapeutic agent that selectively inhibits dipeptidyl peptidase including fibroblast activation protein and dipeptidyl peptidase 8/9 in combination with an immune checkpoint inhibitor. The method specifically discloses use of Talabostat in combination with an immune checkpoint inhibitor, its pharmaceutical composition and process of preparing such composition.
Abstract: Improved anti-CD 154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.
Type:
Application
Filed:
February 1, 2023
Publication date:
January 4, 2024
Inventors:
Jay Rothstein, Robert George Edward Holgate, Arron Hearn
Abstract: A method of treating or preventing the onset of kidney disease comprises administering to a subject a composition comprising an anti-AGE antibody. The anti-AGE antibody binds an AGE antigen comprising at least one protein or peptide that exhibits AGE modifications selected from the group consisting of FFI, pyrraline, AFGP, ALI, carboxymethyllysine, carboxyethyllysine and pentosidine. A method of treating or preventing the onset of kidney disease comprises administering to a subject a vaccine comprising an AGE antigen.
Abstract: The present invention relates to a novel combination of (1) a substance that suppresses or inhibits the function of extracellular TCTP (translationally controlled tumor protein), especially released from tumor cells, and (2) a cancer immunotherapeutic agent for the treatment of cancer. Preferably, such a cancer immunotherapeutic agent is an immune checkpoint inhibitor. The substance that suppresses or inhibits the function of extracellular TCTP functions as an activator or enhancer of anti-tumor immune cells including T cells and natural killer (NK) cells and/or an antagonist of immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs), in the tumor immune microenvironment (TIME). The combination according to the present invention is useful for treating or preventing cancer. The combination according to the present invention is also useful for alleviating, reverting, or preventing immune suppression in the tumor immune microenvironment.
Type:
Application
Filed:
June 30, 2022
Publication date:
January 4, 2024
Applicants:
Boostimmune, Inc., The University of Tokyo
Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Tn antigen or sTn antigen. The compositions disclosed herein include isolated antibody or functional fragments thereof that binds to Tn antigen or sTn antigen and polynucleotides encoding the heavy chain and/or a light chain variable domains of such antibody or functional fragment. The invention also provides methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a localizing agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.
Type:
Application
Filed:
June 1, 2023
Publication date:
January 4, 2024
Inventors:
Godfrey Jonah Anderson Rainey, Wolfgang Walter Scholz, Ritsuko Sawada
Abstract: The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants. In some aspects, pharmaceutical composition is formulated for subcutaneous delivery. In some aspects, the pharmaceutical composition further comprises an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering the pharmaceutical composition.
Type:
Application
Filed:
August 21, 2023
Publication date:
January 4, 2024
Applicants:
Bristol-Myers Squibb Company, Halozyme, Inc.
Inventors:
Masano HUANG, Thomas Arthur HABY, Mehrnaz KHOSSRAVI, Scott Aaron HART, Rao Venkatramana MANTRI, Heather Elizabeth VEZINA, Amit ROY, Bindu Purnima MURTHY, Urvi Ashish ARAS, Kinjal SANGHAVI, Xiaochen ZHAO, Akintunde BELLO
Abstract: In various embodiments, the present disclosure provides T cell compositions comprising T cells that encode and/or express a T cell receptor (TCR) that binds to a neoantigen associated with a subject's cancer, and are useful for adoptive immunotherapy. Also disclosed are methods for making and/or using T cell compositions described herein.
Abstract: The invention described herein provide Kaposi Sarcoma-Associated Herpesvirus (KSHV) oncoprotein antigens and epitopes for expanding antigen-specific T cells. Such expanded T cells are useful for, e.g., in allogeneic or “off-the-shelf” adoptive T cell therapy.
Type:
Application
Filed:
May 2, 2023
Publication date:
January 4, 2024
Inventors:
Catherine Mary Bollard, Danielle Sohai, Conrad Russell Y. Cruz, Thomas Uldrick
Abstract: Provided are a cancer-antigen-specific Natural Killer (NK) cell including a non-viral expression plasmid encoding a chimeric antigen receptor, wherein the chimeric antigen receptor comprises a cancer-antigen-specific single-chain variable fragment (scFv), a hinge region, a transmembrane domain, and intracellular domains; methods of generating said cancer-antigen-specific NK cell; a bispecific antigen-binding molecule comprising a first antigen-binding molecular and a second antigen-binding molecular, wherein the first antigen-binding molecular is an scFv specific to a cancer antigen, and the second antigen-binding molecule is specific to a second cancer antigen and an NK cell receptor, and comprises at least one of an scFv and and an aptamer-based molecule; pharmaceutical compositions comprising at least one of the cancer-antigen-specific NK cell and the bispecific antigen-binding molecule; and methods of treating cancer patients using the pharmaceutical compositions.
Abstract: The disclosure relates to immune cells comprising systems of two engineered receptors each having a ligand binding domain, collectively designed to target cells identified by loss of heterozygosity and used to treat a disease or disorder, for example, cancer. The disclosure provides immune cells expressing two engineered receptors, methods of making same, and polynucleotides and vectors encoding same.
Type:
Application
Filed:
November 23, 2021
Publication date:
January 4, 2024
Inventors:
Carl Alexander Kamb, Agnes Hamburger, Breanna Diandreth, Han Xu, Julyun Oh
Abstract: The present disclosure relates to treating a subject comprising administering to the subject a therapy (e.g., a cell therapy, e.g., an adoptive cell therapy, e.g., a CAR-T cell therapy), wherein, prior to the administration, the subject has been preconditioned with a personalized amount of a chemotherapeutic agent. The personalized amount provides an optimal exposure to the chemotherapeutic agent.
Abstract: The invention concerns a particle and a composition comprising particles and their use in oncology. Specifically, the particles are porous, high-Z and carbon-free particles having internal pores, of longest dimension of at least 0.5 nm, and are for use in altering or destroying target cells in a mammal when said cells are exposed to ionizing radiation. The present invention also provides a porous, high-Z and carbon-free particle wherein at least part of the porous structure of the particle is occupied by at least one therapeutic agent which is preferably for use in oncology.
Abstract: The invention relates generally to protein derivatives containing molecules (e.g., payloads) conjugated to unnatural amino acids (UAAs) by branched linkers, and methods of making and using such protein derivatives.
Abstract: Craniofacial implant composed of PEEK for the prolonged and sustained release of at least one active ingredient soluble in a pharmaceutically accepted vehicle.
Type:
Application
Filed:
January 23, 2023
Publication date:
January 4, 2024
Inventors:
Ilan Bernardo Rosenberg Vaizer, Marcos Alfredo Skarmeta Silva
Abstract: Polyoxazoline polymers, polymer combinations, and compositions comprising those polymers or combinations of polymers are disclosed. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.
Type:
Application
Filed:
September 15, 2023
Publication date:
January 4, 2024
Applicant:
Universiteit Gent
Inventors:
Maarten Vergaelen, Richard Hoogenboom, Victor Retamero de la Rosa, Chris Vervaet, Aseel Samaro, Valérie Vanhoorne
Abstract: The present invention relates to methods of preparing a therapeutic exosome using proteins newly identified to be enriched in the lumen of exosomes. Specifically, the present invention provides methods of localizing a therapeutic peptide or protein in exosomes. The methods involve generation of lumen-engineered exosomes that include one or more of the exosome proteins at higher concentrations, a modification or a fragment of the exosome protein, or a fusion protein of the exosome protein and a therapeutic or a cargo protein.
Type:
Application
Filed:
November 21, 2022
Publication date:
January 4, 2024
Applicant:
LONZA SALES AG
Inventors:
Russell E. MCCONNELL, Kevin P. DOOLEY, Rane A. HARRISON, Ke XU, Damian J. HOUDE, Sonya HAUPT, John D. KULMAN, Douglas E. WILLIAMS, Madeleine YOUNISS
Abstract: The present invention relates to co-amorphous form of a substance and a protein. The present invention also relates to pharmaceutical, cosmetic or veterinary compositions comprising the co-amorphous form as well as to methods for preparing and using the co-amorphous form.
Type:
Application
Filed:
February 8, 2023
Publication date:
January 4, 2024
Inventors:
Jaya Mishra, Adam Bohr, Thilo Berg, Korbinian Löbmann, Thomas Rades, Holger Grohganz, Jorrit Water
Abstract: This invention relates to a field of novel multi-headed compounds capable of binding and inhibiting the catalytic activity of human carbonic anhydrases for diagnostic, visualization, and treatment purposes. A series of compounds containing two or more of carbonic anhydrase inhibitors are linked together via short or long linker molecular moieties. Such dimeric or multimeric inhibitors are designed in such a way that one inhibitor molecule is able to reach several CA IX molecules on the surface of cancer cells. Such compounds are expected to have a significantly more powerful therapeutic effect and may be used for various strategies of specific compound deliveries to the desired site.
Abstract: The present disclosure relates to a selective and efficient method to connect a polypeptide containing at least one lysine residue to a cargo moiety, where one step of the method involves reaction of a semicarbazide group with an ortho-acylphenyl boronic acid, forming a cyclic diazaborine ring fused to phenyl. Conditions for formation of the cyclic diazaborine are sufficiently mild for the method to be used in the presence of sensitive biomolecules such as polynucleotides. A substituent group on the phenyl can be used to link the cyclic diazaborine to a cargo moiety such as a polynucleotide, bead, or reactive group, providing a polypeptide—cargo moiety conjugate that is useful for various purposes, such as to analyze, identify, track, locate, detect, or immobilize the polypeptide. Also provided are polypeptide—cargo moiety conjugates, wherein the polypeptide and cargo moiety are connected via a linker that comprises a cyclic diazaborine.
Abstract: Methods for treating eye diseases, for example eye diseases associated with lipid accumulation, with lipid binding protein-based complexes such as CER-001; lipid binding protein-based complexes, compositions comprising a lipid binding protein-based complex as a carrier for one or more ophthalmic drugs, and uses thereof.
Abstract: The present application is directed to a therapeutically useful compound, comprised of two monomers that are linked to each other through two or more reversible covalent bonds. Each monomer is a polyfunctionalized molecule comprising a bioorthogonal linker element and ligand or pharmacophore, wherein the linker and ligand/pharmacophore are covalently coupled to each other either directly or through an optional connector moiety.
Type:
Application
Filed:
August 4, 2021
Publication date:
January 4, 2024
Inventors:
Francis BARANY, Sarah F. GIARDINA, J. David Warren